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SUMMARY The new scoring system for assessment of 
the extent and severity of skin inflammation index in atopic 
dermatitis patients, W-AZS, is presented. The system 
provides detailed assessment of both subjective and 
objective signs and symptoms of atopic dermatitis. With 
the use of W-AZS, acute and chronic skin manifestations 
of inflammatory process are appropriately evaluated and 
scored. It also enables the practitioner to assess various 
localizations of skin lesions at different time points. W-
AZS is a relatively easy and rapid index to perform, and it 
seems very beneficial for clinicians. Other scoring systems 
used in atopic dermatitis are also presented, analyzed and 
compared, e.g., Atopic Dermatitis Area and Severity Index 
(ADASI), SCORing Atopic Dermatitis (SCORAD), Eczema 
Area and Severity Index (EASI), Six Area, Six Sign Atopic 
Dermatitis (SASSAD), and Three-Item Severity score 
(TIS). There is a strong necessity to standardize clinical 
evaluation of the extent and severity of skin diseases 
such as atopic dermatitis, as laboratory techniques and 
parameters are not really of great use for practitioners.
 
KEY WORDS atopic dermatitis; scoring system; skin 
inflammation; W-AZS
INTRODUCTION
 Objective and detailed evaluation of the signs 
and symptoms of atopic dermatitis (AD) including 
extent and severity of skin inflammation is not an 
easy task. In order to verify the course of the dis-
ease depending on factors such as the treatment 
applied there is a strong necessity of having reli-
able severity scores. The importance of standard-
ized and precise scoring systems is emphasized 
by the increasing need of multicenter trials carried 
out in different countries. Therefore, we should 
evaluate the same clinical parameters and mini-
mize the interindividual differences of scoring that 
may invalidate the data obtained from the studies. 
 
 In general clinical practice, dermatologists rely 
on the screening methods of clinical evaluation of 
the extent and severity of skin inflammation that 
are by no means precise enough. In such cases 
clinical score is defined as mild, moderate or se-
vere, and is definitely neither reliable, nor precise 
or objective. In 1978, Fredriksson and Petters-
son proposed a specific scoring system for clini-
cal evaluation of patients with psoriasis, Psoriasis 
Area and Severity Index (PASI) (1). It is a purely 
clinical method of calculating the score of extent 
and severity of psoriatic skin lesions. PASI score 
has been generally accepted by dermatologists 
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from both clinical and scientific standpoint, and is 
still active in practice. 
 In case of AD patients, the first two scoring 
systems were proposed by Rajka and Lageland 
(2) and Costa et al. (3), both in 1989. The for-
mer designed a very concise scheme based on 
the calculation of simple sum of three parameters 
(extension, course, and intensity). However, this 
scheme is neither precise nor objective. The ex-
tension, course and intensity are scored between 
0 and 3 and based on this system AD could be 
classified as mild (total score 3-4), moderate (from 
>4 to <8) and severe (from >8 to -9). In this scor-
ing system, data obtained from patient history are 
mixed up with the evaluation of itch and extent of 
skin lesions, so the validity of results is low. A more 
precise proposal was that by Costa et al. (3). This 
scoring system is much more complex, calculat-
ing the intensity of 10 signs and symptoms (from 
0 to 7; 0=absence, 7=maximum), along with the 
involvement of 10 different symmetrical regions 
scored from 0 to 3 (0=absence of involvement, 
3=complete involvement). The maximal total score 
is 100 (70 from signs and symptoms, and 30 from 
extension), obtained by simple addition of partial 
scores. The choice of severity criteria was not 
made according to strict evidence and skin lesions 
were evaluated regardless of the stage of inflam-
mation they represented. Costa et al. also evalu-
ated skin pruritus, however, using a very simplified 
scale. In 1991, Bahmer et al. (4) proposed a new 
score, Atopic Dermatitis Area and Severity Index 
(ADASI). It was based on determination of the in-
volved skin surface by point counting. On special 
body diagrams, the areas involved by the inflam-
matory process were color coded according to the 
severity of inflammation (green for mild dermatitis, 
blue for moderate, and red for severe process). 
Then the result was evaluated by applying a trans-
parent grid. To obtain final ADASI score, fractions 
all of the areas involved were weighted and mul-
tiplied by pruritus intensity score. Therefore, the 
final result was highly dependent on the subjective 
grade given for pruritus by the individual patient. 
Additionally, there were certain complications in 
the application of mathematical formulae in the 
process of calculating the final score. 
 In 1992, Sowden et al. (5) presented their pro-
posal. This score evaluated 6 selected skin re-
gions and basic skin lesions. The extent of skin 
inflammation was evaluated according to “the rule 
of nines” on a scale of 0, 3, 6 or 9; the severity of 
skin lesions was graded from 0 to 3. Skin pruri-
tus was measured on the visual analogue scale 
(0-100 mm). This particular method seems to be 
an easy one but evaluates only selected skin ar-
eas and cannot represent the global clinical as-
sessment of the patient. 
 In 1993, after more than 3 years of work, a spe-
cial task force consisting of selected experts pub-
lished another scoring system, SCORing Atopic 
Dermatitis (SCORAD) (6). This system considers 
both objective signs (severity and extension) and 
subjective symptoms (pruritus and loss of sleep). 
On extent evaluation, “the rule of nines” was used 
on a 0-100% scale dividing the whole skin area 
into 11 regions (A). The severity of skin lesions 
(B) was graded from 0 to 3 for 6 selected lesions 
for the representative skin region. This region was 
defined as representing moderate severity of the 
evaluated symptoms in comparison with the re-
maining skin areas. Both pruritus and loss of sleep 
(C) were scored on a 0-10 scale and the values ob-
tained from all three parts of evaluation were then 
processed mathematically according to SCORAD 
specific formula (SCORAD A/5+7B/2+C). This 
score is freely available from an internet site and a 
dedicated software authored by Pelosi and Tripodi 
has been introduced to make the calculation quick-
er. The basic difficulty in appropriate evaluation of 
AD patients by SCORAD system is the issue of 
so-called representative region. In many scientific 
studies we follow patients over various time pe-
riods and therefore the representative region for 
the evaluated skin symptoms will obviously vary. 
We will then end up with some definitely confusing 
clinical score, and building up conclusions on such 
a basis is absolutely uncertain. This is our opin-
ion, perhaps different from other authors because 
this score seems to be still rather popular and has 
been validated in many trials. For some authors, 
SCORAD was too complicated and time-consum-
ing for routine clinical use. Therefore, a simplified 
version, the Three-Item Severity Score (TIS) (7) 
was produced. It seems to be suitable for general 
practice but not for research studies. This scoring 
system evaluates erythema, edema/papulation 
and excoriation on a 0-3 scale.
 In 1996, Berth-Jones (8) established the Six 
Area, Six Sign Atopic Dermatitis system (SASSAD) 
evaluating 6 signs in 6 body regions with a scale 
from 0 to 3. This is a simple and effective tool for 
recording and monitoring disease activity in daily 
practice but it does not include important param-
eters such as pruritus or loss of sleep. It is also 
characterized by significant intraobserver varia-
tion, low reliability and objectivity.
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 Finally, in 1998, an American group proposed 
the Eczema Area and Severity Index (EASI) scor-
ing system (9). This system first multiplies the per-
centage of the affected area of four skin regions by 
a coefficient (head/neck 0.1; trunk 0.3; upper limbs 
0.2; lower limbs 0.4), and then adds this number 
to the severity scores of four signs measured with 
a scale from 0 to 3. EASI ignores pruritus, which 
seems to be a cardinal symptom of AD and there-
fore it does not provide a complete clinical scoring 
method. At present, a modified EASI has been in-
troduced. This system includes a visual analogue 
scale for pruritus (but not for loss of sleep) evalua-
tion. Another variant of EASI named SA-EASI has 
been developed in order to allow self-administered 
assessment of the child to the caregivers (10). 
This is obviously a very specific type of evaluation 
proposed for selected situations. EASI score was 
then modified to mEASI and a new variant Self-
Administered EASI (SA-EASI). 
 None of the scoring systems mentioned above 
is perfect and herewith we present our proposal 
of clinical scoring in AD patients, named W-AZS 
(in Polish terminology: Wskaźnik dla Atopowego 
Zapalenia Skóry; Index for Atopic Dermatitis). It 
is based on our observations and analysis of pre-
vious scoring systems, and has been efficiently 
implemented in various trials performed at our 
Department of Dermatology and Allergic Diseases 
Diagnostic Center.
THE EXTENT AND SEVERITY OF SKIN 
INFLAMMATION INDEX FOR ATOPIC 
DERMATITIS PATIENTS: W-AZS
 This score consists of two basic parts, i.e. eval-
uation of subjective elements (part I) and objective 
symptoms (part II). The global value of W-AZS is a 
simple sum of results obtained in part I and part II.
W-AZS = I + II
I – pruritus and sleep disturbances
II – extent and severity of skin inflammation
 The score for pruritus is related to the ex-
tent, frequency and severity of itching (Table 
1). Depending on pruritus characteristics, pa-
tient’s score may range from 0 to 22 points. 
Sleep disturbances are evaluated on a scale 
from 0 to 12 points (Table 1). The final score for 
part I of W-AZS may range from 0 to 34 points. 
A. PRURITUS EVALUATION
                  POINTS  
      
   No pruritus .....................................................................................................................................................   0 
   Pruritus is present:
    Extent:
1.  Single or multiple localization of pruritus ..................................................................................................... 2 
2.  Extensive pruritus involving the whole body surface.................................................................................... 6
  Frequency:
1.  Short episodes of pruritus - less than 30 minutes ....................................................................................... 2
2.  Longlasting pruritus episodes .....................................................................................................................   4 
3.  Constant pruritus   ...................................................................................................................................... 8
  Severity:
1.  Scratching is not necessary ........................................................................................................................ 2 
2.  Scratching is necessary  ............................................................................................................................. 4 
3.  Anxiety and irritation caused by pruritus ..................................................................................................... 8  
B. LOSS OF SLEEP EVALUATION
1.  No loss of sleep  ..........................................................................................................................................  0   
2.  Problems in falling asleep  ..........................................................................................................................  3 
3.  Night awakening caused by pruritus ...........................................................................................................  6  
4.  Sleeplessness  ............................................................................................................................................ 12  
 
  I = A + B
Table 1.  I – Evaluation of pruritus and loss of sleep in patients with atopic dermatitis
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 Part II of this scoring system evaluates severity 
of skin lesions (Table 2, B), each on a scale of  0 
(absent), 1 (mild), 2 (moderate) or 3 (severe) at 
12 sites of the body surface (face and neck; scalp 
and nucha; trunk – anterior surface; trunk – pos-
terior surface; right arm; right forearm and hand; 
left arm; left forearm and hand; right thigh; right 
shank and foot; left thigh; left shank and foot). Co-
efficient 3 is applied for acute skin lesions (ery-
thema/edema; vesicles/erosions), coefficient 2 for 
crusts and scaling, and coefficient 1 for chronic 
skin lesions (lichenification and pigmentation). 
Therefore, this system has an advantage of differ-
entiating acute and chronic types of inflammatory 
skin lesions. The extent of skin lesions (Table 2, A) 
is measured on a scale of 0 (absent), 1 (1%-10%), 
2 (11%-30%) and 3 (31%-100% of skin surface in-
volved). For precise evaluation there is a specific 
coefficient calculated for each region in relation to 
the surface of the particular site: coefficient 1 for 
4.5%; 2 for 9%, and 4 for 18% of the whole body 
surface. Multiplication of the results calculated for 
the extent and severity of skin inflammation yields 
a value for each particular region (A x B). This val-
ue is then divided by 10, representing the score 
for the region [(A x B):10]. Finally, summing up 12 
results indicates overall extent and severity of skin 
inflammation. The maximum score is 178 points. 
The final step is to sum up the results of part I and 
part II.
DISCUSSION
 An objective and precise clinical scoring system 
for AD patients was one of our aims in the complex 
project on AD launched at the Department of Der-
matology and Allergic Diseases Diagnostic Center 
in Poznań. In 1983, the first proposal was released 
(11). It was a simple method based on evaluation 
of the extent of skin lesions scored between 0 and 
3, and severity of skin inflammation graded from 
0 to 4. This system, although relatively simple, 
was not objective enough and created certain in-
terindividual variabilities. Therefore it could not be 
freely applied in scientific projects. Further investi-
Table 2. II – Evaluation of extent and severity of skin inflammation in patients with atopic dermatitis
• Score extent of skin lesions from 0 to 3:                  • Score severity of skin inflammation from 0 to 3:
         0 = absent  0 = absent
         1 = 1%-10% of skin surface involved  1 = mild
         2 = 11%-30% of skin surface involved  2 = moderate
         3 = 31%-100% of skin surface involved 3 = severe
Total W-AZS : I + II 
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  Extent of skin lesions    A   
Severity of skin inflammation     
erythema      vesicles         crusts       lichenification    B
edema       erosions        scaling      pigmentation
 AxB 
   10        
 1.   Face and neck  
 2.   Scalp and nucha  
 3.   Trunk
       (anterior surface)   
 4.   Trunk         
       (posterior surface)
 5.   Right arm
 6.   Right forearm  
       and hand
 7.   Left arm
 8.   Left forearm
       and hand
 9.   Right thigh
10.  Right shank 
       and foot
11.  Left thigh
12.  Left shank
       and foot
(  )x1=    .....    
(  )x1=    .....
(  )x4=    .....
(  )x4=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....   
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
                                                                         
                                                                  TOTAL   .......
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gations were inspired by PASI score published by 
Fredriksson and Pettersson (1). While working on 
the scoring system we aimed to create an evaluat-
ing method both for subjective and objective signs 
and symptoms for patients with AD. It is obvious 
that a reliable clinical index is absolutely neces-
sary to study a disease using the quality criteria 
required by the modern evidence-based medicine. 
It is also important that the scoring method enables 
the clinician to describe the inflammatory process 
involving all skin regions as well as to compare the 
clinical picture of selected patients at various time 
points. According to W-AZS, clinical evaluation of 
patients is divided into two separate parts: I subjec-
tive elements and II objective features. Therefore, 
depending on the study design, prospective part I 
or part II may also be implemented to the project 
independently. In case of skin pruritus and loss of 
sleep we always rely on patient’s opinion and this 
score is generally difficult and “truly subjective”. 
Our scoring system presents a detailed evalua-
tion of itch graded from 0 to 22 points. For loss 
of sleep scoring we applied values from 0 to 12, 
from absence of loss of sleep to sleeplessness, 
respectively. It seems that evaluation of subjec-
tive features in AD requires a complex approach 
while no objective tools are available. In evalua-
tion of the extent of skin lesions we used “the rule 
of nines“, dividing the overall body surface into 12 
regions (Table 2). The percentage of skin surface 
involved by inflammation was scored as it was 
done in the proposal published in 1983 (11).The 
most important difference has been made in grad-
ing the severity of skin inflammation. We evaluate 
the following skin lesions that are related to the 
inflammatory process: erythema/edema; vesicles/
erosions; crusts/scaling; and lichenification/pig-
mentation. We assumed that various skin lesions 
correspond to different stages (acute, subacute 
or chronic) of the skin inflammatory process and 
therefore we introduced a corresponding coeffi-
cient (from 0 to 3) to the evaluated lesions in cal-
culation of the skin inflammation severity. Such an 
approach has never been proposed before and in 
our opinion it improves considerably the validity of 
the scoring system. Especially in terms of scien-
tific research differentiation of acute and chronic 
skin lesions as representation of the inflammatory 
process seems to be crucial for appropriate clini-
cal scoring. W-AZS may at the first glance be a 
relatively complicated method but when applied in 
practice it appears to be easy and rather simple. 
In our opinion it is a thorough and comprehensive 
system indicated for research purposes. It is rel-
atively little time-consuming, training of the staff 
is easy, and therefore it may be applied to large-
scale epidemiological studies. At the Department 
of Dermatology and Allergic Diseases Diagnostic 
Center, W-AZS has been used for various clinical 
trials for 6 years now and we did not record any 
significant interindividual differences of the evalu-
ations performed (data in press). Therefore, we 
believe that W-AZS meets the criteria of an objec-
tive scoring system for AD patients.
 If we compare W-AZS with other scoring sys-
tems applied in AD evaluation on theoretical ba-
sis, the result is favorable for our index. Obviously 
further studies, especially comparative trials, will 
be performed in the future. We are planning eval-
uation of the objectivity and reliability of W-AZS 
scoring system at our center and in multicenter 
studies. We hope to present the results of these 
projects for publication soon.
 In conclusion, W-AZS is a relatively objective 
clinical scoring system for AD patients. It contains 
evaluation of both objective and subjective features 
in all stages of the disease, describes inflamma-
tory process in all skin regions, and enables us to 
monitor the course of the disease at different time 
points. W-AZS appeared to be a reliable tool in our 
trials (13-17), and considering the fact that none of 
the systems presented above is perfect, we advise 
to consider this index for further investigations. 
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